Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BAY 3375968 |
| Trade Name | |
| Synonyms | BAY3375968|BAY-3375968 |
| Drug Descriptions |
BAY 3375968 is an anti-CCR8 monoclonal antibody, which potentially reduces CCR8-positive regulatory T-cells in the tumor microenvironment through antibody dependent cellular cytotoxicity (ADCC) and cellular phagocytosis (ADCP) (Cancer Res 2022;82(12_Suppl):Abstract nr 2866). |
| DrugClasses | CCR8 Antibody 13 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BAY 3375968 | BAY 3375968 | 0 | 1 |
| BAY 3375968 + Pembrolizumab | BAY 3375968 Pembrolizumab | 0 | 1 |